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AN INHIBITOR OF ANGIOGENESIS ISOLATED FROM BOVINE CORNEA. 
Elizabeth A. Mullen, Rosalind A. Rosenthal, 'Peter V. Hauschka and 
Judah Folkman. Department of Surgical Research, Children's 
Hospital, Boston, MA, 'Department of Orthopedic Research, 
Children's Hospital, Boston, MA. (Sponsored by Caren M. Gundberg, 
Department of Orthopaedics and Rehabilitation, Yale University 
School of Medicine, New Haven, CT). 
The normally avascular cornea paradoxically contains 
stores of a potent stimulator of angiogenesis, basic fibroblast 
growth factor (bFGF) (Am. J. Path. 130:393, 1988). Mun et al. 
reported the partial purification from bovine cornea of a low 
molecular weight molecule which inhibits angiogenesis in the 
chick embryo (Inv Opth & Vis Sci. 30:151, 1989). This factor, 
termed corneal angiogenesis inhibitor (CAI), was also shown to 
antagonize certain bFGF induced effects on capillary endothelial 
cells, including cell migration, cell spreading and cell rounding. 
Endothelial cell rounding in vitro has been correlated with anti¬ 
angiogenesis in vivo (Endocrinology 119:1768, 1986). We report 
an improved purification method for CAI, which like Mun et al. 
used the ability of CAI to cause endothelial cell rounding to 
direct purification. We also measured the ability of CAI to 
inhibit DNA synthesis in endothelial cells, and block angiogenesis 
on the chorioallantoic membrane of chick embryos. Our improved 

purification produced a sample sufficiently pure for preliminary 
structural analysis. This method includes: (1) Dissection of 
bovine corneas; (2) Extraction into 100°C distilled water; (3) 
Filtration of corneas and centrifugation of filtrate; (4) 
Ultrafiltration through pressure dialysis, 1000 molecular weight 
(MW) cutoff, and lyophilization; (5) Extraction in 80% 
dimethylformamide (DMF), centrifugation and evaporation of 
solvent; (6) 100% DMF extraction, centrifugation and evaporation 
of solvent; (7) Reversed phase high performance liquid 
chromatography on both a Cl8 semi-preparative column and a Cl8 
analytical column. Samples purified by this method were 
analyzed by desorptive chemical ionization and electospray mass 
spectroscopy. Possible candidates for the CAI molecule were 
identified at MW 228 and 172. CAI may play an important role in 
the regulation of vascularization in the cornea, perhaps acting as 




The regulation of vascularization is of great importance in 
many normal physiologic and pathologic processes. The term 
"angiogenesis" was introduced in 1935 to describe the formation 
of new blood vessels in the placenta (Hertig, 1935). It is 
currently used to denote the process of generating new capillary 
blood vessels from established vessels, resulting in 
"neovascularization". Under normal physiologic conditions, 
angiogenesis has an essential role in embryonic development, 
ovulation, placental maturation, and wound healing (Jakob et al., 
1977; Gospodarowicz and Thakral, 1978; Wagner, 1980; Bar, 
1980; Hunt et al., 1981). 
Abnormal neovascularization dominates a number of serious 
pathologic conditions, both malignant and nonneoplastic. Much 
evidence exists that solid tumor growth is angiogenesis 
dependent (reviewed in Folkman, 1990; Klagsbrun and Folkman, 
1990) . Tumor angiogenesis and the incidence of metastasis in 
invasive breast carcinoma are highly correlated (Weidner et al., 
1991) . Many diverse diseases (Table 1) in which the dominant 
pathology is persistent neovascularization have been categorized 
as "angiogenic disease" (Folkman and Klagsbrun, 1987). Patients 
affected by angiogenic diseases span a wide range of ages, and 
include both sexes. Care and management of these conditions are 
divided among numerous medical and surgical specialties. For 
example, the excessive proliferation and shedding of the 
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epidermis in psoriasis has been related to abnormal capillary 
growth in the dermis (Ryan, 1970). Hemangiomas can occur in 
newborn babies, with abnormal capillary proliferation persisting 
until up to two years of age, and which in rare cases may result 
in death from hemorrhage ( Folkman, 1984; Folkman and 
Klagsbrun, 1987). All hemangiomas are known to eventually 
regress spontaneously; the mechanism through which this occurs 
is completely unknown. Atherosclerotic plaques can bleed 
secondary to capillary proliferation within the vessel wall, and 
contribute to sudden occlusion of coronary arteries (Barger et al., 
1984). 
Abnormal neovascularization can also affect normally 
avascular tissue, as in rheumatoid arthritis, where the 
occurrence of capillary growth destroys joint cartilage 
(Matsubara and Ziff, 1987; Koch et al., 1986; Crisp et al., 1984). 
Neovascularization in avascular components of the eye leads to 
decreased vision or blindness. Diabetic retinopathy, retrolental 
fibroplasia, and neovascular glaucoma are pathologic conditions 
which involve a breach of the vascular/avascular barriers within 
the eye (Klagsbrun and Folkman, 1990). Disorders involving either 
the corneal epithelium or stroma (Table 2) can result in invasion 
of blood vessels into the avascular corneal stroma, and are a 
leading cause of blindness worldwide (Garner, 1986). 
The control of the stimulation and inhibition of 
angiogenesis has been extensively investigated. A picture has 
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emerged of a regulatory system analogous to other known 
physiologic processes, such as blood coagulation (Folkman and 
Klagsbrun, 1987). Both systems must be maintained in a state of 
inactivity, but constant readiness, over a long period of time. The 
proliferation of vascular endothelial cells in most normal adult 
tissue is measured with turnover time in years (Denekamp, 1984), 
congruent with a microvascular system designed to remain 
quiescent over periods of weeks to decades. The microvascular 
system, however, must be capable of prompt response when faced 
with pathologic conditions or physiologic demands which require 
the rapid growth of new vessels. 
The search for factors which may stimulate or inhibit 
angiogenesis has been extensive. A number of factors, including 
polypeptides and nonpeptide low molecular weight compounds, 
have been shown to be angiogenic in vivo (Klagsbrun and Folkman, 
1990) (Table 3). The process of angiogenesis in vivo is very 
complex. Many sequential steps are required: the degradation of 
capillary basement membrane, the migration and proliferation of 
endothelial cells, and tube formation. One of the earliest 
described stimulators of cell division, basic fibroblast growth 
factor (bFGF) has been found to be a potent stimulator of 
endothelial cell growth and angiogenesis. The term FGF was first 
used to describe a cationic polypeptide isolated from brain in 
1974 (Gospodarowicz, 1974, 1975); its primary amino acid 
structure was described in 1985 (Esch et al., 1985). An anionic 
species of FGF, which was termed acidic fibroblast growth factor 
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(aFGF) was also found in brain, and shown to have a 53% absolute 
sequence homology to the cationic polypeptide, which became 
known as bFGF (Thomas et al., 1980; Lemmon and Bradshaw, 1983; 
Thomas 1987; Esch et al., 1985). The FGFs have since been shown 
to be mitogenic and chemotactic for endothelial cells in vitro, to 
stimulate endothelial cells to produce proteases (collagenase and 
plasminogen activator) which result in degradation of basement 
membrane, and to induce capillary endothelial cells to migrate 
into three-dimensional collagen matrices and form tubes similar 
to capillaries (Gross et al., 1983; Montesano et al., 1986). These 
demonstrated in vitro properties of the FGFs are consistent with 
their observed angiogenic activity in vivo. 
The FGFs are among the most ubiquitous growth factors in 
the body (Folkman and Klagsbrun, 1987). bFGF is found in brain 
(Lobb and Fett, 1984; Gospodarowicz et al., 1984; Bohlen et al., 
1984), eye (Courty et al., 1985), cartilage (Sullivan and 
Klagsbrun, 1985), bone (Hauschka et al., 1986), reproductive 
tissue (Moscatelli et al., 1986), adrenal gland (Gospodarowicz et 
al., 1986), kidney (Baird et al., 1985a), macrophages (Baird et al., 
1985b) and tumors (Shing et al., 1984; Klagsbrun et al., 1986), 
while aFGF is present mainly in neural tissue including brain 
(Lobb and Fett, 1984; Thomas et al., 1984; Conn and Hatcher, 
1984), retina (D'Amore and Klagsbrun, 1984), and eye (Courty et 
al., 1985), and has also been identified in bone (Klagsbrun and 
Folkman, 1990). This extensive distribution raises the question 
of how rampant capillary proliferation is prevented in both 
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normally vascular, and particularly, in normally avascular tissue. 
This question, in turn, has prompted the search for naturally 
occurring inhibitors of angiogenesis. 
The first angiogenesis inhibitor was found in the normally 
avascular cartilage (Eisenstein et al., 1973; Brem and Folkman, 
1975), and has recently been characterized and identified as 
cartilage-derived inhibitor (CDI) (Moses et al., 1990). CDI is a 
member of the tissue inhibitor of metalloproteinase (TIMP) 
family, and has been shown to inhibit angiogenesis in vivo, and 
capillary endothelial cell proliferation and migration in vitro 
(Moses and Langer, 1991; Moses et al., 1990). This protein is also 
an inhibitor of mammalian collagenase. A number of other 
naturally-occurring inhibitors of angiogenesis have been 
identified. These factors include the 16 kDa fragment of 
prolactin (Ferrara et al., 1991), thrombospondin (Good et al., 
1990; Bagavandoss and Wilks, 1990; Taraboletti et al., 1990), 
platelet factor 4 (Maione et al., 1990), and protamine (Taylor and 
Folkman, 1982). Transforming growth factor-beta (TGF-B) (Baird 
and Durkin, 1986; Muller et al., 1987; Jennings et al., 1988), and 
tumor necrosis factor-alpha (TNF-a) (Frater-Schroder et al., 
1987; Schweigerer et al., 1987) are both polypeptides that inhibit 
endothelial cell proliferation in vitro, yet promote angiogenesis 
in vivo and tube formation in vitro . It is possible that TNF-a and 
TGF-B may inhibit the proliferative phase of endothelial cells, 
but promote the differentiation phase, e.g., matrix production and 
tube formation (Klagsbrun and Folkman, 1990). 
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To date, none of these known angiogenesis inhibitors have 
been found in the avascular structures of the eye. However, much 
evidence exists to support the occurrence of endogenous 
inhibition of angiogenesis within the eye. 
The eye contains both vascular and avascular structures 
(Figure 1). The sclera, which comprises the posterior four-fifths 
of the surface of the globe, is composed largely of collagen, 
proteoglycan and fibroblasts. Interestingly, although the sclera 
is interposed between two highly vascular tissues, the episclera 
and the choroid, it is avascular. Inflammatory diseases of the 
ocular surface involving macrophages and bFGF containing mast 
cells, which often result in corneal neovascularization, do not 
cause scleral neovascularization (Sunderkotter et al., 1991). This 
could be attributed to the presence of a potent endogenous 
inhibitor(s) in the sclera. Alternatively, there could be physical 
or mechanical resistance to angiogenesis in the sclera. 
The fetal lens contains hyaloid vessels during embryonic 
development; these regress shortly before birth. Human lens 
epithelium has been shown to contain angiogenic aFGF (Baudouin 
et al., 1990). Paradoxically, extracts of both human and bovine 
lens demonstrate a reversible dose-dependent inhibition of bovine 
aorta endothelial cell proliferation in vitro. This result suggests 
that an extractable, endogenous inhibitor of angiogenesis also 
exists (Williams et al., 1984). It has also been shown that the 
removal of lens and capsule in proliferative diabetic retinopathy 
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leads to an increased incidence of iris neovascularization (Aiello 
et al., 1983). Numerous mechanisms to explain this phenomenon 
have been postulated, including facilitated diffusion of a retinal 
"vasoformative factor" (Ashton, 1957), decreased oxygenation of 
the iris and release of an "iris vasoformative factor" (Schulze, 
1967), and reduced endogenous inhibition from the lens (Williams 
et al., 1984). 
The aqueous humor fills the anterior chamber, and 
physically contacts the cornea, lens, iris, ciliary body and 
trabecular meshwork. It has been demonstrated that normal 
aqueous humor inhibits capillary endothelial cell proliferation in 
vitro, while it promotes a dose-dependent proliferation of 3T3 
smooth muscles cells and dermal fibroblast in vitro (Okamoto et 
al., 1990). Interestingly, it was also found that this anti- 
angiogenic activity is absent in the aqueous humor of diabetic 
rabbits. The identity or source of the proposed endogenous 
inhibitor has not been elucidated. 
The vitreous humor occupies the chamber anterior to the 
retina and posterior to the lens. It is composed of water, 
collagen, hyalocytes, and the proteoglycan hyaluronic acid. 
Clinically, the vitreous appears to be resistant to angiogenesis. 
In proliferative diabetic retinopathy, fronds of developing blood 
vessels grow onto the vitreous surface, but do not penetrate its 
substance. Interestingly, the vitreous from patients with 
diabetic proliferative retinopathy has been shown to contain 
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elevated levels of bFGF (Sivalingam et al., 1990). This 
observation suggests the possibility of an increase in the ratio of 
angiogenesis stimulators to inhibitors in the vitreous in this 
disease. As evidence of the angiogenic potential of the vitreous, 
degradation products of vitreous hyaluronic acid assayed on the 
chick chorioallantoic membrane (CAM) were shown to induce 
neovascularization (West et at., 1985). However, vitreous has 
also been shown to be inhibitory of angiogenesis. Angiogenic 
tumors implanted into the vitreous remain small and avascular - 
unless they happen into direct contact with the retina (Brem et 
al., 1976). Extracts from the vitreous have been shown to inhibit 
both retinal extract-induced angiogenesis, and tumor-induced 
angiogenesis (Lutty et al., 1985). These findings support the 
concept of regulatory interplay between both inhibitory and 
stimulatory factors of angiogenesis which, under normal 
conditions, maintain an avascular state in the vitreous. 
Neovascularization of the retina is a serious consequence of 
several pathologic conditions; diabetes, sickle cell anemia, 
branch vein occlusion, and retrolental fibroplasia (Patz, 1982). 
Blindness results from vitreous hemorrhage and retinal 
detachment following the development of new blood vessels in 
the retina (Ashton, 1983). Studies have shown that retina 
contains endothelial cell growth factors, including aFGF and bFGF 
(Baird et al., 1985), as well as serum factors such as platelet 
release factors (Miyazono et al., 1987), and insulin-like growth 
factors (Grant et al., 1987; King et al., 1985). However, more 
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recently McIntosh and co-workers showed that retinal extract 
inhibited the serum-induced proliferation of retinal capillary 
endothelial cells (McIntosh et al., 1989). This finding suggests a 
regulatory system for vascularization within the retina involving 
a balance of angiogenesis stimulators and inhibitors. 
The normally avascular cornea is paradoxically known to 
contain large stores of angiogenic bFGF (Folkman et al., 1988). 
The bFGF has been shown to bind to Bowman's layer, the acellular, 
most anterior portion of the collagenous corneal stroma, which is 
rich in proteoglycan (Adamis et al., 1991). BFGF is also found in 
Descemet's membrane, a true basement membrane produced by 
corneal endothelial cells on the posterior surface of the cornea 
(Figure 2). Folkman and co-workers demonstrated that bFGF could 
be released from the cornea by treatment with heparin, heparan 
sulfate, or heparanase (Folkman et al., 1988). Their work 
suggested that sequestration of this angiogenic endothelial 
mitogen in the basement membrane could be a general mechanism 
for controlling the accessibility of bFGF to vascular endothelium, 
therefore regulating vascularization. The abnormal release of 
bFGF could be the cause of corneal vascularization in a number of 
ocular diseases. In support of this concept, injury-induced 
release of bFGF from corneal epithelial cells has recently been 
demonstrated (Adamis et al., 1991). 
As an alternate, or additional explanation for the 
maintenance of avascularity of the cornea in the presence of 
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angiogenic bFGF, the existence of an angiogenesis inhibitor in the 
cornea was hypothesized. A number of studies supported this 
hypothesis. Corneal extracts which were mitogenic for 
endothelial cells were found to be inhibitory of cell growth at 
high concentrations (Folkman et al., 1988). When pieces of cornea 
from several animal species were placed onto the chorioallantoic 
membrane (CAM) of a developing chick embryo (Folkman, Casey, 
Levenson, unpubl. results), avascular zones appeared around the 
corneas. These corneas could be moved to another chick embryo, 
and again, an avascular zone on the CAM surrounding the cornea 
would be produced. This suggested the production of a diffusible 
angiogenesis inhibitor by the cornea. 
A systematic search for this corneal angiogenesis inhibitor, 
termed CAI, was undertaken. A partial purification scheme was 
established by Susan Doctrow, Edward Mun, and Judah Folkman, 
and many characteristics of the molecule defined. The inhibitor 
was found to stable to boiling and pronase digestion. Sensitive 
amino acid analysis techniques revealed no amino acids, 
indicating the inhibitor is not a peptide. Bioactivities of the 
partially purified CAI were also characterized. In addition to the 
inhibition of angiogenesis on the CAM assay, CAI was shown to 
cause inhibition of DNA synthesis in endothelial cells, and 
inhibition of bFGF stimulated cell migration, in a Boyden chamber 
model (Mun et al., 1989). Partially purified CAI blocks both 
attachment (cell number analysis) and cell spreading of bovine 
capillary endothelial (BCE) cells in response to bFGF 
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(morphometric analysis) (Carter, Ingber, Folkman, unpubl.). 
Staining with antibodies to vimentin demonstrates disconnection 
of the intermediate filaments from the plasma membrane, 
followed by the depolarization of actin. Associated with the 
inhibition of cell spreading, corneal extracts can also cause 
endothelial cells to "round", in a dose-dependent manner. This 
rounding effect can be reversed by titration with bFGF. Rounded 
cells exclude trypan blue, and stain with fluorescein diacetate, 
indicating viability. Inhibition of cell migration was observed 
with the lowest quantities of CAI, followed by DNA synthesis 
inhibition, and endothelial cell rounding. Angiogenesis inhibition 
on the CAM required the most material. 
A semi-quantitative screening assay based on the cell 
rounding effect of CAI was designed to guide the further 
purification of this molecule (Mun et at., 1989). In large part, the 
purification was hampered by inconsistent behaviors and 
reproducibility of results, particularly in achieving binding to 
high-pressure liquid chromatography (FIPLC) column resins. 
In our work, we have further improved the purification of 
CAI, while retaining its bioactivity. Aqueous extraction, 
ultrafiltration, organic extraction, and reverse phase high- 
pressure liquid chromatography were used to reproducibly obtain 
a partially pure preparation of CAI, suitable for preliminary 
analysis by mass spectroscopy. 

METHODS 
Cell Culture - Bovine capillary endothelial (BCE) cells were 
isolated from bovine adrenal glands as described by Folkman et 
al., (1979), except 5 p/ml crude retinal factor (Gitlin and 
D'Amore, 1983) was used instead of mouse sarcoma conditioned 
medium. BCE cells are usually maintained in Dulbecco's modified 
Eagle's medium (DMEM), containing 25 pg/ml endothelial mitogen 
(BTI), 10% calf serum, 2 mM glutamine, and antibiotics. 
Endothelial Cell Rounding Assay - The samples to be tested 
on the rounding assay were first dried in a model TM 100 
SpeedVac Concentrator (Savant), and then dissolved in rounding 
assay media (DMEM, 10% calf serum, 20 mM HEPES pH 7.4, 2 mM 
glutamine and antibiotics). Bovine capillary endothelial cells 
were seeded onto 96 well half-area plates (0.16 cm2 wells ) 
(CoStar), at a density of 2000 cells per 25 pi per well, in 
rounding assay medium. After a 6 - 12 hour attachment period, 
the cells were treated with serial dilutions of inhibitor fractions 
(Figure 3). Cells were examined by phase microscopy after 6 - 24 
hours, and judged for cell rounding. One unit of cell rounding is 
defined as the amount of sample which is sufficient to cause 
rounding in 50% of the cells in a given well (Figure 41. The 
number of rounding units in a given sample is calculated from the 
greatest dilution of sample which will produce one unit of cell 
rounding. 
' 
DNA Synthesis Assay - Bovine capillary endothelial cells 
are plated on 48 well plates (CoStar) at a density of 7500 
cells/well in DMEM containing 2% calf serum, 3 pM thymidine, 2 
mM glutamine, and antibiotics. After a 24 hour attachment 
period, the medium is exchanged with rounding assay medium, the 
samples are added, and the cells are incubated for an additional 
18 hours at 37°C. The cells are then incubated with 1 pCi 3H- 
thymidine/well (82.2 Ci/mmol) for 6 h. The cells are washed 
once with phosphate-buffered saline (PBS). The cells are 
subjected twice to a wash of cold methanol for 5 minutes each 
wash, and twice to cold 5% trichloroacetic acid for 10 minutes 
each. The plates are washed briefly with water and 0.3 M NaOH is 
added. The NaOH-solubilized material is transferred to vials 
containing scintillation fluid. The sample is neutralized with 
glacial acetic acid, and the vials are counted in a Beckman model 
LS 3801 scintillation counter. 
Chick Chorioallantoic Membrane (CAM) Assay - The CAM 
assay is performed as described by Crum et al. (1985). The 
sample to be tested for stimulatory or inhibitory properties is 
combined with a carrier of 0.45% methylcellulose (10 pi), and air 
dried to form a disc of 2 mm diameter. This disc is applied to the 
shell-less embryo in a cultured petri dish (Auerbach et al., 1974; 
Klagsbrun et al., 1976; Folkman, 1985). After incubation at 37°C 
in 3% CO2 for 48 hours, the embryos are examined under a 
dissecting microscope (6X power). An embryo is scored as 
negative (indicating inhibition) if an avascular zone larger than 4 
' 
mm2 is observed (Figure 51. Positive angiogenic activity is 
revealed by the radical ingrowth of new vessels. Inhibition or 
stimulation of neovascularization can be confirmed by histologic 
microsections of India-ink-injected specimens (Haudenschild, 
1980). 
PURIFICATION SCHEME 
Dissection - Bovine eyes (-70°C), with the eyelids 
removed, were obtained from BioResources, Texas, and the 
corneas were dissected immediately upon arrival. The eyeballs 
were rinsed briefly in cold distilled H2O, and the corneas 
carefully excised from the frozen eyes, using a number 15 scalpel 
blade (Figure 6). The corneas were placed on dry ice, and stored 
at -80°C until use. 
Extractions - To begin the extraction of CAI, frozen 
corneas (500) were placed in a 1 liter Erlenmeyer flask, with 500 
ml of HPLC grade H2O (Pierce HPLC grade solvents were used 
exclusively throughout the purification). The flask was put into a 
hot water bath, brought to 100°C, and boiled for 20 minutes. The 
hot extract was filtered through coarse Whatman filter paper 
under vacuum, to remove the corneas and debris. The filtrate was 
centrifuged for 15 minutes at 10,000xg, and the supernatant 
retained. The supernatant was subjected to ultrafiltration using 
an Amicon YM2 (1000 molecular weight cut-off) membrane under 
55 psi nitrogen pressure, overnight at 4°C. The filtrate was 

collected and lyophilized. The lyophilized powder was 
reconstituted with 10 ml of H2O. Dimethylformamide (DMF, 90 
ml) was added, and the solution stirred at room temperature for 1 
hour. The material was then centrifuged in glass tubes for 20 
minutes at lO.OOOxg. The supernatant was dried in a model EL 
131 RotoVapor (Buchi). DMF (25 ml) was added directly to the 
round bottom RotoVapor flask, and the flask agitated at room 
temperature for 1 hour. This material was centrifuged for 20 
minutes, and the supernatant retained and stored at 4°C. 
High-Pressure Liquid Chromatography 
C18 Analytical HPLC column - Initial investigation of the 
binding and elution of CAI was performed using a Supelco 
octadecylsilica (Cl 8 reversed phase) analytical (15 cm X 4.6 mm) 
HPLC column. DMF extracted material (1 ml) was dried in 12 X 
75mm borosilicate tubes in a SpeedVac rotor (Savant), and 
resuspended in 100 pi of H20, 0.1% trifluoroacetic acid. This 
sample was injected onto the column, and washed with a complex 
gradient of O -100% acetonitrile, 0. 1% trifluoroacetic acid (TFA) 
(Figure 71. Fractions (2 ml) were collected, and dried in a Speed 
Vac. Absorbance of the fractions eluting from the column was 
monitored at 220nm. These fractions were saved for assay in the 
endothelial cell rounding assay, DNA synthesis inhibition, and 
CAM assay. 
C18 Semi-preparative HPLC column - A similar technique 
was employed when using the Cl8 semi-preparative HPLC column. 

The 100% DMF extracted material (3ml) was dried and 
resuspended as above, in 0.1% TFA (200 pi). This sample was 
injected onto a Cl8 semipreparative (25 cm X 10mm) HPLC column 
(Supelco), and absorbance of eluted fractions again measured at 
220 nm (Figure 81. Fractions were collected and assayed for 
bioactivity. 
Cl8 Analytical HPLC column - second HPLC purification 
step. A single fraction (fraction 13) obtained from the Cl8 semi¬ 
preparative column which demonstrated the greatest number of 
units of endothelial cell rounding activity was selected and dried. 
This fraction was reconstituted in 100 pi of H20, injected onto a 
Supelco C18 analytical (15 cm X 4.6mm) HPLC column (Supelco), 
and eluted with a complex gradient of O - 50% acetonitrile, in the 
absence of trifluoroacetic acid (Figure 91. Fractions were 
collected by hand, as individual peaks of absorbance seen at 220 
nm. These samples representing individual peaks of absorbance 
were assayed for bioactivity using the endothelial cell rounding 
assay, and the elution fractions which contained bioactivity were 
determined. This second HPLC purification step was repeated 
under exact conditions, using identical starting sample material. 
Identical (superimposable) chromatographs were obtained. These 
fractions were similarly collected by hand, as individual peaks, 
and retained for mass spectroscopy investigations (Figure 10). 
Mass Spectroscopy - As detailed in the previous section, 
fractions which eluted from the C18 analytical column 
. 
purification step identically to those which had demonstrated 
bioactivity were collected in pre-weighed 12 x 75 baked glass 
tubes, dried in a SpeedVac, and submitted for structural analysis 
to SmithKIine Beecham Pharmaceuticals (Michael Huddleston, 
Steven A. Carr, Ph.D.). Additionally, the fractions representing 
absorptive peaks which did not demonstrate bioactivity were 
submitted for comparative studies. All samples were analyzed by 
electrospray mass spectroscopy (ESMS), and bioactive fractions 
were analyzed by desorptive chemical ionization (DCI) in both 
positive and negative ion modes, using both ammonia and 
isobutane as the reagent gases (Steven Carr, personal 
communication). 
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RESULTS 
Previously, a method of extraction and partial purification 
of CAI from bovine cornea was established by Susan Doctrow and 
Ed Mun. A schematic of their method is given in Table 4. and in 
Table 5. a schematic of the improved purification method which 
we have established is presented. In the previous scheme, 
corneas purchased from BioResources were extracted in 10% 
ethanol, overnight in the cold. Ethanol was employed to control 
bacterial overgrowth. A second two hour extraction followed, and 
the extract was boiled for 15 minutes after which the corneas 
were removed by filtration. The extract was passed through a 
membrane with a MW cut-off of 1000, and the filtrate 
lyophilized. Two chloroform : methanol (50:50) extractions were 
performed, and the soluble fraction was retained and dried on a 
RotoVapor. Several conditions for high pressure liquid 
chromatography were employed, but successful binding and 
elution of the CAI activity could not be reproducibly achieved 
with the chloroform:methanol extracted material. 
We have developed an improved purification method for CAI. 
In order to better control for the preparation and storage of our 
starting material, we obtained frozen whole bovine eyes, and 
dissected the corneas in our laboratory directly upon arrival from 
BioResources. Next, the corneas were boiled in HPLC H2O for 20 
minutes. The resultant extract yielded the same or higher amount 
of rounding activity/cornea as the longer cold extraction of the 

previous method, but had a lower protein content, and less visible 
debris. Significant advantages of this step are also the reduction 
in time from 28 to 2 hours, and elimination of the need for 
ethanol, which must be removed later in the purification. 
The ultrafiltration step remains unchanged in the current 
method. This step yields an 80% recovery of rounding activity 
after filtration (Table 6). We have recently found that a second 
ultrafiltration step, using a membrane with a 500 MW cut-off and 
identical conditions, yields an 80% recovery of activity that had 
been recovered after the first ultrafiltration step (1000 MW cut¬ 
off filter). 
The major modification in the current method is the organic 
extraction performed. In the current method, DMF is added to a 
concentrated aqueous solution of the CAI, to produce a final 
concentration of 90% DMF. This instantly produces a large, 
flocculent precipitate. After centrifugation, almost 90% of the 
rounding activity is recovered in the supernatant, and none is 
detected in the pellet. A subsequent 100% DMF extraction yields 
more precipitated material, and 85 - 90% recovery of rounding 
activity. The results of these extractions compare favorably 
with the result of the organic extraction of the previous 
purification methods. The chloroform:methanol extraction 
yielded only a 50% recovery of activity in the soluble fraction, 
with a nearly equal amount of activity detectable in the insoluble 
material, even after two overnight extractions. 
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The material obtained from the DMF extractions also 
demonstrated the ability to inhibit DNA synthesis, as partially 
purified CAI by the previous method did (Figure 11). There is 
significant inhibition of DNA synthesis, at concentrations of CAI 
much less than required for rounding activity. Similar results 
had been found with the chloroform: methanol extracted material. 
The most important outcome of the DMF extractions was 
that with this material, we were able to establish conditions to 
consistently bind and elute CAI activity from HPLC Cl 8 reverse 
phase columns. Figure 7 shows a chromatograph obtained by using 
a Cl8 analytical column, and running a complex gradient from O to 
100% acetonitrile, with 0.1% trifluoroacetic acid. Fractions were 
collected and assayed for rounding activity. Fractions 2 - 14 all 
showed some rounding activity, but two major peaks of activity 
were demonstrated. The early fraction were very acidic, with a 
pH of 5 in the most concentrated samples in the cell rounding 
assay. In order to test if all the rounding activity seen in these 
fractions correlated with anti-angiogenic activity, we tested the 
fractions on the CAM assay. The results are presented in Table 7. 
Fractions from the Cl8 column were pooled into four groups. Pool 
1-4 and 10-13 showed similar amounts of endothelial cell 
rounding activity, the other pools less. Pool 1-4 was clearly 
toxic to the embryos, killing 4/5. The one surviving egg had no 
avascular zone. In contrast, the pool of fractions 10-13 showed 
dramatic anti-angiogenic activity, with 5/5 large avascular 
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zones. The other pools showed no toxicity, and both demonstrated 
some weak anti-angiogenic activity. 
In order to increase the amount of CAI purified, we scaled 
up the purification using a C18 semipreparative column. The 
larger column yielded better resolution and separation, again, 
with two major peaks of rounding activity seen (Fig ure Q). 
Interestingly, the fractions collected from this column which 
were highly acidic were fraction 3 and 4, and no rounding activity 
was seen in these fractions. 
As the next step in the purification, a single fraction from 
the semipreparative column containing high rounding activity was 
selected, and run on the Cl8 analytical column. A more gradual 
gradient of acetonitrile, without TFA, was utilized, in an attempt 
to obtain further separation of the bioactive material. The 
resultant chromatograph contained only a few well-delineated 
peaks, and was found to be highly reproducible, run under 
identical conditions, using identical starting material (Figure 9T 
The peaks seen on the Cl 8 analytical chromatograph were 
collected by hand, and dried in a SpeedVac. Presumably identical 
fractions were obtained from consecutive runs: one set was 
devoted towards assay for endothelial cell rounding activity, and 
was set was prepared and retained for analysis by mass 




Because of the concern of possible toxicity in the 
bioactivity assays from the use of organic solvents throughout 
the purification, a blank run of the entire purification scheme 
was performed, and samples from each stage of the purification 
were tested on the endothelial cell rounding assay. All samples 
demonstrated no cell rounding, and no toxicity to the cells was 
observed. These blank samples, produced by following the 
purification scheme, were also submitted with the active 
samples for mass spectroscopy analysis, to rule out artifactual 
results. 
The mass spectroscopy analysis showed a consistent 
species of molecular weight 228 in electrospray mass 
spectroscopy (ESMS) and desorptive chemical ionization (DCI). A 
gas phase exchange experiment indicated that the molecule has 
three exchangeable hydrogens (H). The electrospray data was 
clouded by very strong signals derived from sodium 
trifluoroacetate. A unique peak was seen at m/z 173 (possible Mr 
= 172). This signal, however, was not observed in the DCI, and 
could not be pursued further. 
Electrospray and DCI mass spectra was also 
performed on blanks which had been submitted. These blanks 
were obtained by performing the entire purification scheme, 
without the corneas. It was concluded that the extraction 
process and solvents were not contributing to the observations 
which had been made about the active samples. 
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Scanning high resolution was next attempted on these 
partially analyzed samples, however, the sample was found to be 
inadequate, secondary either to insufficient quantity, or 




This paper describes the further characterization and 
purification of a novel corneal angiogenesis inhibitor, initially 
described by Mun et al. (1989). Three different assays were used 
to assess the bioactivity of partially purified samples of CAI. 
Primarily, BCE rounding activity has been used to guide the 
purification. Retention of the ability to inhibit DNA synthesis by 
BCE cells, and to generate avascular zones on the CAM has also 
been demonstrated throughout the purification. 
A major difficulty in the previous purification scheme was 
the inability of the CAI partially purified by chloroforrmmethanol 
extraction to reproducibly bind to and elute from an HPLC column. 
The finding that CAI was soluble in DMF enabled the use of HPLC 
for further purification of the molecule. There are several 
reasons why the DMF extraction facilitated HPLC purification. The 
DMF extraction could have removed contaminating impurities from 
the CAI and enabled binding to the Cl8 column. Alternatively, DMF 
extraction could have caused a chemical alteration of the CAI 
molecule, of a carrier, or an associated molecule. This alternative 
seems less likely, since BCE DNA synthesis inhibition, BCE 
rounding activity, and CAM angiogenesis inhibitory activity were 




Two clearly distinct peaks of rounding activity eluted 
from both the analytical and semi-preparative Cl 8 HPLC columns 
(Figures 7-9). Pools of the fractions from the peaks observed on 
the first analytical column separation were also analyzed for DNA 
synthesis inhibition and angiogenesis inhibition on the CAM. The 
material from the later eluting peak of rounding cell activity 
clearly retained both the ability to inhibit BCE DNA synthesis, and 
the ability to cause avascular zones in the CAM assay. The early 
eluting peak from the Cl8 column was found to have rounding 
activity, and it inhibited BCE DNA synthesis. This material did not 
cause avascular zones on the CAM assay, however 4/5 of the 
embryos died with this treatment, suggesting toxicity. 
Investigation of the ability to inhibit angiogenesis in the CAM 
assay has not yet been carried out with material from the Cl 8 
semi-preparative column. The first peak of rounding cell activity 
from this column is better separated from the bulk of UV- 
absorbing material than with the analytical column. It is possible 
that the semi-preparative column might provide separation of 
cell-rounding activity from the material which was toxic on the 
CAM assay. If isolated from toxic substances, the material from 
early peak of rounding cell activity may also inhibit angiogenesis 
on the CAM assay. This early eluting material could represent an 
alternate form of the CAI. It is possible that the CAI exists as a 
dimer, or multimer. Alternatively, a carrier molecule could be 
associated with the CAI molecule. 
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The second peak of cell rounding activity which eluted from 
the Cl 8 column also demonstrated inhibition of DNA synthesis, 
and inhibition of angiogenesis on the CAM, therefore this material 
was selected for further purification. Because of difficulty in 
finding another HPLC resin to which the CAI would bind, the 
ability of CAI to bind to C18 was further exploited. A single 
semi-preparative column fraction which demonstrated the highest 
endothelial cell rounding activity (fraction 13) was selected, and 
run on the Cl 8 analytical column under slightly different solvent 
conditions. Selection of a single fraction of the CAI activity peak 
for the next stage of the purification entailed a significant 
sacrifice of active material. If all active fractions from the HPLC 
column were recombined, this step involved about a 30% loss of 
activity from the material loaded onto the column. By selecting 
only a single active fraction, only 5-10% of this activity was 
utilized in the next step of purification. Accepting such a 
significant sacrifice of active material is an obvious disadvantage 
to the purification scheme. However, this method does yield a 
high degree of purification which we hoped to be sufficient for 
structural analysis. The chromatograph obtained from the Cl8 
analytical run of fraction 13 showed few well-delineated peaks 
(Figure 10). Multiple runs of the C18 analytical column, using 
fraction 13 from multiple runs of the C18 semi-preparative 
column, provided identical chromatographs. These peaks were 
collected as separate fractions for examination of bioactivity. 
Endothelial cell rounding activity was observed in two of the 
fractions collected from the column (peaks 1 and 5). Because the 
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peaks from the analytical column eluted sharply and seemed to 
represent single species, it was decided that this material might 
be pure enough for further analysis by mass spectroscopy and that 
valuable structural information might be obtained from this 
analysis. There was not enough material accumulated from the 
Cl8 analytical column to also establish anti-angiogenic activity 
on the CAM assay. This work is in progress. 
By mass spectroscopy, possible candidates for the active 
CAI molecule were found at MW 228 and 172. The 228 species was 
also found in desorptive chemical ionization. Gas exchange was 
employed to show that this molecule had 3 exchangeable 
hydrogens (by comparison with NH3 or ND3 as the reagent gases), 
and possible alcohol functions (mass 18 losses). The molecule 2- 
deoxyuridine fits this description. Therefore this compound was 
assayed for BCE rounding activity at concentrations up to 10 mM. 
No rounding activity was observed. However, it is possible that 
CAI may be co-purified with a carrier or associated molecule 
which may be required for bioactivity. One approach to test this 
theory would be to add 2-deoxyuridine to samples of CAI with 
known activity, and look for enhancement of the bioactivity. 
Characterization of the CAI molecule has revealed new 
information. It is a molecule of very low molecular weight. It is 
stable to boiling and freezing. It has shown resistance to pronase 
digestion. Furthermore, sensitive amino acid analysis indicates 
that it is not a peptide. On the other hand, solubility and 
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chromatography behaviors of the CAI molecule are consistent with 
those of a polar lipid. Based on these characteristics, possible 
candidates for the identity of CAI include sphingolipids, 
glycolipids, or their metabolites. Recent reports demonstrate 
that these molecules can perform roles in regulation of 
vascularization. 
Sphingolipids and sphingolipid breakdown products have been 
shown to have important roles in cell regulation and physiology 
(Hannun and Bell, 1989). Breakdown products and metabolites of 
these cellular lipids include arachadonic acid, prostaglandins, 
leukotrienes eicosanoids, thromboxanes (Needleman et ai, 1986; 
Samuelsson et ai, 1987), and diacylglycerol (Nishizuka, 1986). 
These molecules may function as endogenous modulators of cell 
function (Hannun and Bell, 1989). Prostaglandins Ei and E2 have 
been demonstrated as nonpeptide angiogenic factors (BenEzra, 
1978: Ziche et ai, 1982; Form and Auerbach, 1983), and proposed 
to have a role in rheumatoid arthritis, tumor induced angiogenesis, 
and lymphocyte induced angiogenesis (Form and Auerbach, 1983). 
The role of prostaglandins in the eye is not well known; however a 
recent study of the influence of a fish oil dietary supplement on 
immunogenic keratitis has looked indirectly at this question 
(Verby and Van Haeringen, 1990). In this study, rabbits were given 
either a fish oil diet, or a sunflower seed oil diet, before immune 
complex keratitis was induced by corneal intrastromal injection 
of human serum albumin. Fish lipids are known to contain large 
amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid. 
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These fatty acids are known to have an effect on prostaglandin and 
leukotriene synthesis. The sunflower seed diet is rich only in 
linoleic acid, which does not influence the production of either 
prostaglandins or leukotrienes. The animals which were given the 
fish oil diet showed significantly less neovascularization, 
leukocyte infiltrate, and corneal edema, as compared to the 
animals fed a sunflower seed oil diet. This study provides a 
provocative inference that eicosanoids, either prostaglandins or 
leukotrienes, may play an important role in the inhibition of 
angiogenesis in the cornea. 
An arachadonic acid metabolite produced by the cornea has 
been recently described as a potent, dose dependent, chemotactic 
and angiogenic factor (Masferrer et al., 1991). Cytochrome P450 
from human and bovine corneal epithelium have been shown to 
convert arachadonic acid to 12(R)-hydroxy-5,8,14(Z,Z,Z)- 
eicosatrienoic acid (compound D) (Masferrer et al., 1989) (Murphy 
et al., 1988). This metabolite has inflammatory properties 
including stimulation of vasodilation and breakdown of the blood- 
aqueous barrier (Masferrer et al., 1989). Human, bovine, and rabbit 
corneas have also been shown to metabolize arachadonic acid to 
12(R)-hydroxy-5,8,10,14 eicosatetraenoic acid [12(R)HETE], which 
is an inhibitor of Na+-K+-ATPase (Schwartzman et al., 1987). The 
actual role of this molecule in the cornea has not been described. 
Again, given the characteristics of the partially purified CAI, 
further investigation in the potential relationship to the corneal 
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cytochrome P450 arachadonic acid metabolites is certainly 
warranted. 
In summary, a reproducible and straightforward method of 
extraction and partial purification of CAI from bovine cornea has 
been established. Successful purification of an angiogenesis 
inhibitor from cornea is of great potential significance. Because 
it is of low molecular weight and naturally occurring, this 
compound has the potential to serve as a diffusible, non-antigenic 
treatment of corneal neovascularization and possibly, of other 
angiogenic-dependent diseases. Another potential use of purified 
CAI might be to improve the storage of corneas prior to corneal 
transplant. It is well known that there is a high incidence of 
endothelial rejection and graft failure in corneal transplants in 
which the recipient beds are vascularized is high (Khodadoust, 
1973). A storage solution containing added CAI might help tp 
prevent neovascularization of the transplanted corneas. This 
exogenously added CAI could diffuse into the cornea and make it 
less angiogenic. In the current aqueous solutions, endogenous CAI 
can presumably diffuse out of the stored cornea and into the 
storage solution, leaving bFGF in Bowman's layer and Descemet's 
membrane, which can lead to increased neovascularization. 
Finally, discovery of the structure of this anti-angiogenic 
compound may help elucidate the mechanism of its role in 
counteracting angiogenic factors such as bFGF. It is quite 
possible that the same or very similar compounds may be found in 
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DISEASES MANIFESTING PATHOLOGIC ANGIOGENESIS 
Ophthalmology Orthopedics 




























TABLE 1 - This table represents a group of 
diseases previously thought to be unrelated, however, 
it has been recognized that the principle pathologic 
feature of each of these conditions is the abnormality 
of capillary blood vessel growth. Furthermore, there 
is the possibility that therapeutic control of the 
abnormal capillary growth could eliminate other 
manifestations of the disease. (Adapted from 
Klagsbrun and Folkman, Angiogenesis. Handbook of 
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PURIFIED ANGIOGENIC FACTORS 
GROWTH FACTOR MOLECULAR WEIGHT 
Basic FGF 18 000 
Acidic FGF 16 500 
VEGF 45 000 
Angiogenin 14 100 
TGF - a 5 500 
TGF - p 25 000 
TNF - a 17 000 
Platelet-derived ECGF 45 000 
Angiotropin 4 500 
1 -Butyryl-glycerol 306 
TABLE 3 - These factors have been shown to be 
angiogenic in vivo, and include polypeptide and 
nonpeptide low molecular weight compounds (Dobson 





CAI PREVIOUS PURIFICATION METHOD 
Extract frozen bovine corneas in 10% ethanol, 24 hrs,4°C 
Filter to remove corneas 
Re-extract corneas in 10% ethanol, 2 hrs, 4°C, filter 
Boil filtrates, 10 min, centrifuge 
Evaporate ethanol on Rotovapor, 1 hr 
Ultrafiltration of supernatant, 1000MW cut-off filter 
Lyophilize filtrate 
Extract in 1:1 chloroform:methanol, 18-24 hrs, 25°C, centrifuge 
Re-extract pellet in 1:1 chloroform:methanol, 2 hrs, 25°C, centrifuge 
Combine supernatants from chlorofornrmethanol extractions 
Dry on RotoVapor 
TABLE 4 - A method of extraction and partial 
purification of CAI from bovine cornea established by 
Susan Doctrow and Ed Mun is presented above. 
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CAI CURRENT PURIFICATION METHOD 
Extract frozen bovine corneas in 100°C distilled H2O, 20 min 
Filer to remove corneas, centrifuge filtrate 
Ultrafiltration of supernatant, 1000MW cut-off filter 
Lyophilize filtrate 
Extract in 90% dimethylformamide (DMF), 1 hr, 25°C 
Centrifuge, dry supernatant on RotoVapor 
100% DMF extraction, 1 hr, 25°C 
Dry extract in Speed Vac 
FIPLC Cl8 Semi-preparative column 
Elute with 0 - 100% acetonitrile, 0.1% trifluoroacetic acid 
HPLC Cl8 Analytic column 
Elute with 0 - 50% acetonitrile 
TABLE 5 - This schematic represents the 
current CAI partial purification method. This method 
has demonstrated improvement in reproducibility, and 
more significantly, DMF extraction of CAI has allowed 
for consistent utilization of FIPLC to obtain further 
purification. 
. 
ACTIVTY YIELDS OF THE CURRENT CAI PURIFICATION 
Boiling Extraction 100% 
Ultrafiltration 80% 
90% DMF Extraction 90% 
100% DMF Extraction 85% 
Semi-preparative Cl 8 HPLC 
- all active fractions totaled 
70% 
Single fraction (13) - selected for 
further HPLC purification 
5-10% 
Cl8 analytical HPLC column 
- total of active fractions 
80% 
TABLE 6 - The above table presents the approximate 
yields of activity of each step in the purification 
scheme. Activity is based on observed bioactivity in 
the semi-quantitative BCE rounding cell assay. 
Activities were calculated as the % of activity 
retrieved from the total activity of the starting 




ANTI-ANGIOGENIC ACTIVITY OF Cl8 HPLC FRACTIONS 








I - 4* 126 0 % Toxic to 4/5 eggs 
5-9* 81 20 % 1/5 small zone 
10 - 13* 114 100 % 5/5 large avascular 
14 - 16’ 18 40 % 2/5 small zones 
Fractions pooled from 6 runs of CIS HPLC analytical column 
TABLE 7 - Fractions collected from a sample of 
100% DMF extracted CAI material run on a Cl8 
analytic HPLC column (Figure 7) were pooled into 
four groups: Fractions 1-4, 5-9, 10-13, 14-16. The 
samples were assayed for BCE rounding activity and 
angiogenesis inhibition on the CAM. The pool of 
fraction 10-13 showed dramatic anti-angiogenic 





OF THE VASCULAR AND AVASCULAR STRUTURES 
OF THE BOVINE AND HUMAN EYE 
CORNEA 
FIGURE 1 - The eye is divided into vascular 
and avascular zones. The cornea, lens, sclera, 
aqueous humor and vitreous humor are all normally 
avascular zones. Infringement of blood vessel 
growth into these tissues can lead to decreased 





SCHEMATIC REPRESENTATION OF 
HISTOLOGIC SECTIONS OF THE CORNEA 
CORNEAL EPITHELIUM*, 





FIGURE 2 - Bowman's layer is the acellular, 
anterior-most portion of the collagenous corneal 
stroma, rich in heparan-sulfate proteoglygan. 
Descemet's membrane is a true basement membrane 
produced by corneal endothelial cells on the posterior 
surface of the cornea. Both layers bind bFGF (Adamis 
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CAI TREATED BOVINE 
CAPILLARY ENDOTHELIAL CELLS 
FIGURE 4 - Bovine capillary endothelial cells were 
plated at a density of 2000 cells per 25 pi per well, in 96 
well 1/2 area plates. These cells were treated with serial 
dilutions of CAI inhibitor samples (decreasing 
concentrations from left to right). The inhibitor causes 
rounding of the cells after 10-24 hours, in a concentration 
dependent manner. One unit of cell rounding as defined as 
the amount of sample sufficient to cause rounding of 50% of 
the cells in a given well. The cells in the middle well above 
would be scored as 50% round. The rounded cells exclude 





CAI INHIBITION OF ANGIOGENESIS ON THE 
CHICK EMBRYO CHORIOALLANTOIC MEMBRANE 
FIGURE 5 - Application of a sample of partially 
purified CAI to the chorioallantoic membrane of a six- 
day chick embryo causes capillary regression and 
produces a 4 mm avascular zone at 48 hrs, indicating 
inhibitory activity. The chick embryo was injected 
with India ink prior to dissection to improve 
visualization of the vessels. (Photo courtesy of Susan 
Doctrow and Ed Mun). 
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BOVINE CORNEA DISSECTION 
FIGURE 6 - Bovine eyes (-70°C) were rinsed 
briefly in cold distilled H2O, and the cornea carefully 
excised from the frozen eye using a number 15 scalpel 





























C18 ANALYTIC HPLC COLUMN 
100% DMF EXTRACTED CAI SAMPLE 
Cl 8 Analytical Column 
Fractions 
FIGURE 7 - This chromatograph was obtained 
with a sample of CAI which had been extracted in 
100% DMF. CAI rounding cell activity was found to 
consistently bind and elute from the Cl8 analytic 
column as shown above. Two major peaks of rounding 
cell activity were observed, and fractions from both 
peaks also inhibited BCE DNA synthesis. Only the 
second peak, however, was shown to have angiogenic 













































C18 SEMIPREPARATIVE HPLC COLUMN 
100% DMF EXTRACTED CAI SAMPLE 
Cl 8 SEMI-PREPARATIVE COLUMN 
Fractions 
FIGURE 8 - In order to increase the amount of 
CAI purified using Cl 8 HPLC, a semipreparative Cl 8 
HPLC column was employed. Using the larger column, 
better resolution and separation of CAI bioactivity 
was obtained. As with the analytical column, two 
major peaks of BCE rounding activity were observed. 
Notably, fractions 3 and 4 collected from this column 

































C18 ANALYTICAL HPLC COLUMN 
SECOND HPLC PURIFICATION STEP 
Cl 8 Analytical HPLC Column 
C 18 se-mi—preparative column fraction 13 
minutes 
FIGURE 9 - To further the purification of CAI, a 
single fraction from the Cl 8 semi-preparative column 
(Fraction 13) which contained high BCE rounding 
activity (Figure 8) was selected, and run on a Cl8 
analytical column, with a 0 - 50% gradient of 
acetonitrile (no TFA). The above chromatograph was 
obtained, and the individual peaks collected as 












CIS ANALYTICAL HPLC COLUMN 
BIOACTIVITIES AND WEIGHTS OF SAMPLES 
SUBMITTED FOR MASS SPECTROSCOPY 
FIGURE 10 - Fractions were collected as 
marked on the chromatograph (1 - 5), and assayed for 
rounding activity. Fraction 1 contained 7 units of 
rounding activity, fraction 5 contained 6 units. 
Another run was performed under identical 
conditions, and these same fractions were collected 
in baked glass tubes, dried in the SpeedVac, and 
weighed. These samples were submitted for mass 





























EFFECT OF CAI ON BCE DNA SYNTHESIS 
o-o 50 jj,\ 
• -• 200 fi\ 
* cells rounded 
FIGURE 11 - CAI partially purified by DMF 
extraction which had demonstrated bioactivity in the 
BCE rounding assay was assayed for bioactivity in a 
DNA synthesis experiment. The DMF extracted CAI 
sample demonstrated significant inhibition of DNA 
synthesis, at concentrations of CAI much less than 
required for rounding activity. Similar results had 
been obtained with the chloroform:methaol extracted 
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